Surmodics to Webcast Third Quarter Fiscal 2019 Earnings Conference Call on July 31
- Wall St bounces back on boost from banks, industrials
- Dollar dips after Fed rally, Bitcoin slumps
- Oil steady on summer demand hopes but Iranian supply looms
- Bitcoin (BTC) and Ethereum (ETH) Plunge as China's Crackdown on Mining Intensifies, One-Third Of Global Processing Power Now Shut
- Headwinds are Building, Prepare for a Significant Market Correction, Says Top Market Analyst
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Webcast is Live at 4 p.m. (CT)
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2019 conference call on Wednesday, July 31, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.
Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will recap the third quarter fiscal 2019 financial results and accomplishments. To access the webcast, go to the investor relations portion of the Company’s website at https://surmodics.gcs-web.com the day of the conference call and click on the webcast icon.
An audio replay will be available beginning at 7 p.m. CT on Wednesday, July 31, until 7 p.m. CT on Wednesday, August 7, and can be accessed by dialing 888-203-1112 and entering conference call ID passcode 6653187. In addition, the conference call audio and transcript will be archived on the Company’s website following the call.
About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address unmet clinical needs for its medical device customers and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.
Source: Surmodics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lydall (LDL) to be Acquired by Clearlake Capital-Backed Unifrax for $62.10 Per Share
- Arrival (ARVL) Announces Effectiveness of Registration Statement
- U.S. Steel (X) Q2 EPS Guidance Tops Consensus
Create E-mail Alert Related CategoriesPress Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!